As none of the tumours sequenced herein had been exposed to rituximab at the time of biopsy, the effect of these genetic alterations is presumed to also provide a selective advantage in lymphomagenesis, suggesting an oncogenic function for FCGR2B. Further exploration of the processes leading to FCGR2B over-expression in DLBCL is warranted. The gene discussed is FCGR2B; the disease is diffuse large B-cell lymphoma.